Press Releases

Date	Title
2/23/12	AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Corporate Update Conference Call
2/22/12	AVI BioPharma Regains NASDAQ Compliance
2/9/12	Results From Phase I Clinical Trials Demonstrate Positive Safety Data of AVI BioPharma's RNA-Based Therapeutics for Treatment of Ebola and Marburg Viruses
2/2/12	AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO & Investor Conference
1/4/12	AVI BioPharma Data Safety Monitoring Board Reports No Safety Concerns Identified in Phase IIb DMD Clinical Trial, Recommends Continuation of Trial
12/14/11	AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
12/9/11	AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
11/22/11	AVI BioPharma to Present Company Overview at the Piper Jaffray Health Care Conference
11/15/11	AVI Enters Into Collaborations for the Development of Two Additional Exon-Skipping Products for Duchenne Muscular Dystrophy (DMD)
11/8/11	AVI BioPharma to Present Company Overview at the Lazard Capital Markets 8th Annual Healthcare Conference

IR Menu